Survey
* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project
Clinical Investigation and Outcomes Research Analysis of Physiologic and Pharmacologic Data Marcia A. Testa, MPH, PhD Department of Biostatistics Harvard School of Public Health 1 Objective of Presentation • Introduce analytical methods for the special case where biomedical data are collected during a session which contains: – repeated observations over time – numerous, frequently sampled data points – measures collected over a relatively short interval of time (several hours or days) within one session – commonly, more measures per session per subject, than subjects overall 2 Intensively Sampled Data • Data collected during a physiology, monitoring or pharmacologic study over several hours or days with measurement every 1, 5, 10, 15, 30 or 60 minutes, or as a continuous function • Each session may be repeated at weekly or monthly intervals to investigate the effects of interventions as part of clinical trials or treatment assessment, and to correlate session summary parameters with clinical events, morbidity and mortality • In physiologic research, these data are often referred to as “complex physiologic signals” 3 Why Study Signals? ECG BP Physiologic signals and time series reveal aspects of health, disease, biotoxicity and aging not captured by static measures. Time = 2 seconds Raw (original) signals are of interest as means of developing new biomarkers measuring parameters of known interest developing new insights into basic mechanisms of human physiology 4 Physiologic Response Periodic Functions Time (minutes) Response may represent a periodic function such as this graph of interstride intervals for a patient with Huntington’s disease, or a smooth function in response to a stimulus 5 such as oral drug administration. Plasma concentration Smooth Functions 14 Ka = Absorption Constant Ka/Ke=10 12 Ke = Elimination Constant Ka/Ke=1 10 Ka/Ke=0.1 8 Ka/Ke=0.01 6 4 2 0 0 Oral Drug 5 10 TIME (hours) 15 20 6 Intensive Data: Cardiology Studies • Continuous recording: ECG is recorded continuously during the entire testing period. • Event monitor, or loop recording: ECG is recorded only when the patient starts the recording, when symptoms are felt. 7 A Complex Signal Dataset Physiologic time series, such as this series of cardiac interbeat (RR) intervals measured over 24 hours, can capture some of the information lost in summary statistics. Data from the NHLBI Cardiac Arrhythmia Suppression Trial (CAST) RR Interval Sub-study Database 8 Example 1: Heart Rate Dynamics Pathology can affect physiologic recordings in unexpected and interesting ways. Analysis of complex signals can extract information hidden in data. Figure shows shows the instantaneous heart rates of four subjects. The plot of heart rate (beats/min) versus time (min) is called a tachogram. Of the four tachograms shown, only one signal is from a healthy person. Can you tell which it is? 9 Excessive regularity Healthy heart rate Excessive regularity Uncorrelated Randomness In A and C we can see a rather periodic signal, with low variability of its values. In case C, there is a pattern of periodic oscillations (1/min), which is associated with CheyneStokes breathing. The healthy record B is characterized by a rather rough and ‘patchy’ configuration, attributed to fractal properties of the heart rate signal. The breakdown of such behavior (fractal dynamics) can lead to either excessive regularity (A &C) or 10 uncorrelated randomness (D). A Example 2: Ambulatory ECG Schedule of study events is shown in panel A. B Panel B shows inhospital activity schedules on the two activity days. AEM indicates ambulatory ECG monitoring. Vertical arrows represent timing of venous sampling. 11 Example 2: Rates of Ambulatory Ischemia – Bar Graphs and Polynomial Regression Regular Activity Day Parker JD, Testa MA, Jimenez AH, Tofler GH, Muller JE, Parker JO and Stone PH. Morning increase in ambulatory ischemia in patients with stable coronary artery disease: Importance of physical activity and increased cardiac demand. Circulation 1994;89:604-614. 12 Example 2: Rates of Ambulatory Ischemia – Bar Graphs and Polynomial Regression Delayed Activity Day Parker JD, Testa MA, Jimenez AH, Tofler GH, Muller JE, Parker JO and Stone PH. Morning increase in ambulatory ischemia in patients with stable coronary artery disease: Importance of physical activity and increased cardiac demand. Circulation 1994;89:604-614. 13 A Regular Activity Day B Delayed Activity Day Example 2: Ambulatory ECG Bar graphs show frequency of episodes of ambulatory ischemia during therapy with placebo and nadolol on the two activity days. Panel A, Regular activity day;panel B, delayed activity day. 14 Example 2: Minute by Minute Heart Rate Placebo Nadolol Parker JD, Testa MA, Jimenez AH, Tofler GH, Muller JE, Parker JO and Stone PH. Morning increase in ambulatory ischemia in patients with stable coronary artery disease: Importance of physical activity and increased cardiac demand. Circulation 1994;89:604-614. 15 Example 2: Minute by Minute Heart Rate Placebo Nadolol Parker JD, Testa MA, Jimenez AH, Tofler GH, Muller JE, Parker JO and Stone PH. Morning increase in ambulatory ischemia in patients with stable coronary artery disease: Importance of physical 16 activity and increased cardiac demand. Circulation 1994;89:604-614. Example 3: Continuous Glucose Monitoring in Diabetes Continuing Glucose Monitoring Systems Each colored line represents 5-minute glucose samples for a different day of the week. 17 Intensively sampled data can arise from many sources during the same clinical study Continuing Glucose Monitoring Systems Glucose Meter E-Diary 18 Example 4: Pharmacokinetics • Pharmacokinetics provides good general framework for the family of models which involves extracting parameters representative of biological processes – Drug absorption, distribution, metabolism and excretion – Intensity and duration of therapeutic and toxic effects of many drugs are closely related to their biological availability and disposition 19 Example 4: Plasma Concentration of Drug after Oral Administration 5 Elimination phase 4 3 2 1 Absorption phase 0 -1 -10 0 10 20 30 40 Time in Hours 20 Steps in Analysis 1. Collect raw signal data (e.g., heart rate, glucose, plasma concentration) and transfer to relational database for estimation of parameters 2. Estimate signal parameters (e.g., heart rate variability, glucose variability, pharmacokinetic rate constants) using analytical programs 3. Use estimated parameters as dependent measures for prediction of health outcome or mortality (Exposed vs Unexposed), or determine how treatment (e.g., beta blocker) changes signal and how that change impacts health outcome, clinical event or mortality (Experimental vs. Control) 21 Disease Hypertension Authors Guzzetti 1991 Langewitz 1994 Saul 1998 Heart failure NYHA III &IV Cardiomyopathies Sudden death-heart attack Ventricular arrhythmias Study Population Methods 49 with hypertension versus 30 controls 34 with hypertension vs 54 controls Autoregressive modeling (AR) Fast Fourier transformation (FFT) 25 with heart failure vs 21 controls 10 with heart failure vs 10 controls 12 with heart failure Statistical methods 4 minutes FFT FFT and statistical methods Counihan 1993 104 patients with myo-cardiopathy FFT and statistical methods Algra 1993 193 survivors vs 230 controls 22 survivors vs 22 controls Statistical methods in 24 recordings Autoregressive modelling in 24 hour Holter Biknley 1991 Townend 1992 Huikuri 1992 Huikuri 1993 18 patients with ventricular fibrillation Autoregressive modelling in 24 hour Holter recordings Clinical Findings LF in hypertension, HF component and loss of circadian variation (both studies) Low HRV HF ( 0,1 Hz) LF/HF ↑ HRV with treatment with inhibitors of converting activation enzyme (ACEs) HF ( 0,1 Hz) ↓HRV induces ↑in mortality by a factor of 2.6 ↓ HF in survivors ↓ of all HRV components before the arrhythmic episode 22 Estimating HRV Parameters Hear Rate Variability (HRV) Adapted from Goldberger AL. Fractals dynamics in physiology: Alterations with disease and aging. PNAS 2002; 99: 2466-2472, downloaded from www.physionet.org. 23 HRV: Time-Domain Methods • Based upon beat-to-beat or RR intervals – SDRR: standard deviation (SD) of RR intervals over 24 hours – SDARR: SD of average RR intervals calculated over short periods ( 5 mins) – RR50: number of pairs of successive RRs that differ by more than 50 minutes. 24 HRV: Frequency-Domain Methods • Fast Fourier transform • High Frequency band (HF) between 0.15 and 0.4 Hz. HF is driven by respiration and appears to derive mainly from vagal activity (parasympathetic nervous system). • Low Frequency band (LF) between 0.04 and 0.15 Hz. LF derives from both parasympathetic and sympathetic activity and has been hypothesized to reflect the delay in the baroreceptor loop. 25 HRV: Frequency-Domain Parameters • Fast Fourier transform • Very Low Frequency band (VLF) band between 0.0033 and 0.04 Hz. The origin of VLF is not well known. • Ultra Low Frequency (ULF) band between 0 and 0.0033 Hz. The major background of ULF is day– night variation and therefore is only expressed in 24hour recordings. • The ratio of low-to-high frequency spectra power(LF/HF) has been proposed as an index of sympathetic to parasympathetic balance of heart rate fluctuation, but this is controversial because of the lack of understanding of the mechanisms for the LF 26 component. HRV: Non-linear Methods • Poincaré plot. Each data point represents a pair successive beats, the x-axis is the current RR interval, while the y-axis is the previous RR interval. • HRV is quantified by fitting mathematically defined geometric shapes to the data. • Other methods used are the correlation dimension, nonlinear predictability, point wise correlation dimension and approximate entropy. 27 Poincaré plot The abscissa represents the RR interval of the current normal beat and ordinate represents the RR interval of the succeeding normal beat. An ellipse is fitted to the data points and the Poincaré plot indices are calculated by estimating the short diameter (SD1), the long diameter (SD2) and the ratio of the short and long diameters (SD1/SD2 ratio) of the fitted ellipse 28 Pharmacokinetic Processes • Liberation – the release of the drug from its dosage form • Absorption – the movement of drug from the site of administration to the blood circulation • Distribution – the process by which the drug diffuses or is transferred from intravascular space to extravascular space (body tissues) • Metabolism – the chemical conversion of drugs into compounds that cab be eliminated • Excretion – the elimination of unchanged drug or metabolite from the body via renal, biliary, or pulmonary processes. 29 Elimination Constant First order elimination, rate is proportional to concentration. The elimination rate constant Kel represents the portion of the drug eliminated per unit time. 30 Elimination Constant (Log scale) The slope of the line of the concentration plotted on the log scale correlates with Kel. Kel = ln(Peak/Trough)/time (P-T)) 31 First Order Process T = 0, C = 100 dC Loss from 1 to 2 is proportional to C L(2, 1) dt First order rate constant SIDE A SIDE B COMP 1 COMP 2 32 Calculation of Parameters 33 How do you estimate parameters? There are several software packages that can be used to estimate parameters – such as those from www.adinstruments.com as 34 shown here. How do I estimate parameters? There are several software packages that can be used to estimate parameter – such as those from www.adinstruments.com as 35 shown here. Pharmacokinetic Analysis Software Several different packages may be used. e.g.,(shown) http://www.summitpk.com/ 36 www.physionet.org NIH has a data archive and free software. 37 What is Physionet? • NIH-sponsored Research (Harvard, BU, McGill) established in 1999 • Freely available physiologic data and open-source software • PhysioBank: 4000 recordings of digitized physiologic signals and time series, over 40 databases • PhysioToolkit: Open source software 38 Physionet Tutorials and Data http://www.physionet.org/tutorials/hrv/ 39 Continuous Glucose Monitoring (CMG) 40 Continuous Glucose Monitoring (CGM) 41 Data for Sample Patient – 4 Days Is the “mean” the best way to summarize these data? 42 Data for Sample Patient – Session Week 12-- there are many parameters that could be estimated for each subject 43 Summarize the Raw Data • The individual daily curves should be summarized to obtain signal parameters meaningful to the research objectives • Examples – – – – – Mean, Max, Minimum for each day Percent > 180 mg/dl (hyperglycemia) Percent < 36 mg/dl (severe hypoglycemia) Intraday standard deviation (glucose variability) Area above and below defined thresholds 44 Simple Numeric Transformations /BREAK=Patient_ID by CGMS_num by Date by Nocturnal /Sensor_Glucose = NU(Sensor_Glucose) Data Reduction from /Sensor_1 = MEAN(Sensor_Glucose) /Sensor_2 = MEDIAN(Sensor_Glucose) 1000’s to only 15 /Sensor_3 = SD(Sensor_Glucose) measures per subject /Sensor_4 = MIN(Sensor_Glucose) – all representing a /Sensor_5 = MAX(Sensor_Glucose) /Sensor_6 = PGT(Sensor_Glucose 140) different parameter of /Sensor_7 = PLT(Sensor_Glucose 70) the CGMS profile /Sensor_8 = PGT(Sensor_Glucose 180) curve /Sensor_9 = PLT(Sensor_Glucose 60) /Sensor_10 = PLT(Sensor_Glucose 50) Code Shown – using /Sensor_11 = PGT(Sensor_Glucose 300) /Sensor_12 = MEAN(Sens_gluHI) functions from a /Sensor_13= MEAN(Sens_gluLO) common statistics /Sensor_14 = SD(Sens_gluHI) package or Excel. /Sensor_15= SD(Sens_gluLO) 45 More Sophisticated Modeling Techniques: Fourier Series Start with a sine wave: Build a model using Fourier Series The theory of Fourier series lies in the idea that most signals, can be represented as a sum of sine waves 46 CGM Daily Measures • • • • • • Mean Glucose (24-hour, day-time, nocturnal) Mean Glucose Standard Deviation Mean amplitude glucose excursions (MAGE) Low blood glucose index (LBGI) High blood glucose index (HBGI) AUC of BG < 70 mg/dL (3.9 mmol/L) and < 50 mg/dL (2.8 mmol/L) • Nocturnal hypoglycemia – measures < 36, 50, or 70 mg/dL during late night and early morning (sleep time) 47 CGM Post-Prandial Measures • • • • • • • • • • • Some summary Meal Interval Start Glucose parameters may be Meal Interval Start Time in response to Pre-Meal Insulin Dose meals. Meal Type Glucose (C0 (mg/dl), Time (0) Glucose Cmax (mg/dl), Glucose Tmax (min), Glucose (Cmax - C0), Glucose (Tmax - T0), Glucose Cmin (mg/dl - trough) Glucose Tmin (min) Glucose (Cmax – Cmin ) Glucose Upstroke (Appearance Rate) Glucose Downstroke ( Elimination Rate) 48 Data for Sample Patient • The patient had three sessions of continuous glucose monitoring with each session lasting several days. • Below are the overall mean glucoses for each of the sessions Case 100000.0 100000.0 100000.0 Week 0 12 24 Initials Mid Interval Date Glucose XYZ XYZ XYZ 20-OCT-2009 15-JAN-2010 06-APR-20`0 185.33 133.63 133.90 49 Graph of Mean Glucose at Weeks 0, 12 and 24 for Patient 100000 190 180 Mean of Sensor_Glucose 170 160 150 140 130 120 1 2 3 CGMS-Session 0 12 24 Weeks 50 Number of Glucose Values 15 patient feasibility study Each patient is measured during 3 session (Week 0, 12 and 24). Each session lasts r 3 – 5 days with measures taken every 5 minutes yielding a maximum of 288 values per day. Clinic 1 ID 200000’s Clinic 2 ID 400000’s What is the mean glucose, glucose variability and hyper and hypoglycemia parameters for the subjects at Week 12? There are a total of 13,050 glucose measures for 15 patients. 51 15 patient feasibility study The 13,050 glucose measures for these 15 patients are reduced to 4 summary parameters for each patient -yielding 60 summary parameters in total for the 15 patients. Summary Parameters 1. Mean Glucose 2. Glucose Variability (SD Glucose) 3. Percent values > 140 mg/dL (hyperglycemia) 4. Percent values < 70 mg/dL (hypoglycemia) 52 Glycemia CGM Parameter Estimates at Week 12 Here we summarize the parameters for the 15 subjects. In the next session we will learn how to construct confidence intervals and develop different hypotheses for these measures. 53 Summary • Identified the types of clinical research studies requiring analytical methods for complex data signals and parameter estimation • Reviewed various analytical techniques and software packages for obtaining clinical physiology and pharmacologic methods • Introduced examples in cardiology (HRV) and CGM (diabetes) where such techniques are useful 54